The author discusses the need for stability analysis.
Quality risk management is an essential element of every aspect of drug development and manufacturing throughout the product lifecycle.
A 10-step systematic approach to analytical method development and validation can improve the quality of drug development.
Harmonized regulations call for a risk-based and systematic approach to evaluating and selecting CPPs.